Efficacy and safety of a novel anti-HER2 therapeutic antibody RC48 in patients with HER2-overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single-arm phase II study.
Sign Up to like & getrecommendations! Published in 2021 at "Cancer communications"
DOI: 10.1002/cac2.12214
Abstract: BACKGROUND Current treatment options for human epidermal growth factor receptor 2 (HER2)-overexpressing gastric cancer at third-line have shown limited clinical benefit. Further, there is no specific treatment for HER2 immunohistochemistry (IHC) 2+ and fluorescence in-situ… read more here.
Keywords: patients her2; her2 overexpressing; junction cancer; gastroesophageal junction ... See more keywords
Treatment in esophagogastric junction cancer: Past, present and future.
Sign Up to like & getrecommendations! Published in 2019 at "Cirugia espanola"
DOI: 10.1016/j.ciresp.2019.03.016
Abstract: Adenocarcinomas of the gastroesophageal junction represent 27% of all gastric tumors. n recent years, it has been classified as an entity of its own, with specific treatments that are sometimes differentiated from gastric treatments. Treatment… read more here.
Keywords: treatment esophagogastric; junction cancer; treatment; cancer past ... See more keywords
Surgical and perioperative treatment strategy for resectable esophagogastric junction cancer.
Sign Up to like & getrecommendations! Published in 2022 at "Japanese journal of clinical oncology"
DOI: 10.1093/jjco/hyac019
Abstract: Esophagogastric junction cancer is defined as adenocarcinoma with the epicenter within 5 cm of the esophagogastric junction in the West according to the Siewert classification. In contrast, it is defined as cancer of any histological type… read more here.
Keywords: cancer; junction cancer; treatment; surgical perioperative ... See more keywords
Clinicopathological characteristics of patients with HER2-positive gastric and gastroesophageal junction cancer in a single tertiary hospital.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2021.39.15_suppl.e16105
Abstract: e16105 Background: Gastric cancer (GC) and gastroesophageal junction cancer (GEJ) are the second most prevalent and lethal digestive malignancies worldwide. According to GLOBOCAN 2020, the incidence in Mexican population is 4.5% and represents 7% of… read more here.
Keywords: junction cancer; toga trial; cancer; gastroesophageal junction ... See more keywords
Prognostic Significance of Sarcopenia in Patients with Esophagogastric Junction Cancer or Upper Gastric Cancer
Sign Up to like & getrecommendations! Published in 2017 at "Annals of Surgical Oncology"
DOI: 10.1245/s10434-017-5811-9
Abstract: BackgroundThe association between sarcopenia and postoperative outcomes for patients with gastrointestinal malignancies remains controversial. This study aimed to assess the impact of sarcopenia on short- and long-term outcomes after surgery for esophagogastric junction cancer (EGJC)… read more here.
Keywords: sarcopenia; junction cancer; gastric cancer; cancer ... See more keywords
PD-1 inhibitor combined with apatinib for advanced gastric or esophagogastric junction cancer: a retrospective study
Sign Up to like & getrecommendations! Published in 2020 at "Translational cancer research"
DOI: 10.21037/tcr-20-1333
Abstract: Gastric or esophagogastric junction cancer (GC/EGJC) is the third leading cause of cancer-related deaths worldwide, with most of the cases diagnosed at late stages (1,2). For patients (pts) with unresectable or recurrent advanced GC/EGJC, systemic… read more here.
Keywords: gastric esophagogastric; inhibitor combined; junction cancer; cancer ... See more keywords
Immune-related adverse events associated with immune checkpoint inhibitors for advanced gastric and gastroesophageal junction cancer: A meta-analysis
Sign Up to like & getrecommendations! Published in 2023 at "World Journal of Gastrointestinal Oncology"
DOI: 10.4251/wjgo.v15.i2.352
Abstract: BACKGROUND Immune checkpoint inhibitors (ICIs) have shown promising efficacy in treatment and clinical management of advanced gastric and gastroesophageal junction cancer. However, the inhibitors also cause immune-related adverse events (irAEs). The current systematic review and… read more here.
Keywords: incidence; advanced gastric; gastroesophageal junction; iraes ... See more keywords
Blood-based Markers in the Prognostic Prediction of Esophagogastric Junction Cancer
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Cancer"
DOI: 10.7150/jca.44545
Abstract: Esophagogastric junction cancer poses a great threat to human beings both in western countries and East Asia, especially in China and Japan, and its incidence has increased during recent decades. The 5-year survival rate of… read more here.
Keywords: cancer; esophagogastric junction; junction cancer; blood based ... See more keywords